Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women

Clinical Cancer Research

Volumn 13, Issue 2 I, 2007, Pages 408-414

  Maruyama, Naomi ^a   Miyoshi, Yasuo ^a   Taguchi, Tetsuya ^a   Tamaki, Yasuhiro ^a   Monden, Morito ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; GOSERELIN; METHOTREXATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA POLYPEPTIDE; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; JAPAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CARCINOMA; CATALYTIC DOMAIN; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JAPAN; LYMPHATIC METASTASIS; MUTATION; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33846854921     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0267     Document Type: Article

References (40)

1. Osaki M, Oshimura M, Ito H. PI3K-AKT pathway: its functions and alterations in human cancer. Apoptosis 2004;9:667-76.
2. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signaling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
3. Stephens L, Williams R, Hawkins P. Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 2005;5:357-65.
4. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5.
5. Cheng JQ, Ruggeri B, Klein WM, et al. Amplication of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Prc Natl Acad Sci U S A 1996;93:3636-41.
6. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253:239-54.
7. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
8. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65:4562-7.
9. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-73.
10. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005;102:802-7.
11. Saal LH, Holm K, Maurer M, et al. PIK3CA Mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-9.
12. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-8.
13. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
14. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-5.
15. Broderick DK, Di C, Parrett TJ, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2005;64:5048-50.
16. Wang Y, Helland A, Holm R, Kristensen GB, Borresen-Dale AL. PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005;25:322.
17. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequency mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-80.
18. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41:1649-54.
19. Li VSW, Wong CW, Chan TL, et al. Mutaitons of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005;5:29.
20. Wu G, Xing M, Mambo E, et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005;7:609-16.
21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
22. Kourea HP, Koutras AK, Scopa CD, et al. Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma. Mol Pathol 2003;56:328-35.
23. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006;96:91-5.
24. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Panel Members. Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 2005;16:1569-83.
25. Kucab JE, Lee C, Chen CS, et al. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 2005;7:796-807.
26. David O, Jett J, LeBeau H, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004;10:6865-71.
27. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
28. Miyoshi Y, Iwao K, Takahashi Y, Egawa C, Noguchi S. Acceleration of chromosomal instability by loss of BRCA1 expression and p53 abnormality in sporadic breast cancers. Cancer Lett 2000;159:211-6.
29. Park BK, Zeng X, Glazer RI. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res 2001;61:7647-53.
30. Thant AA, Nawa A, Kikkawa F, et al. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis 2000;18:423-8.
31. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3 kinase/AKT pathways. Oncogene 2005;24:7443-54.
32. Grille SJ, Bellacosa A, Upson J, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003;63:2172-8.
33. Buttitta F, Felicioni L, Barassi F, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006;208:350-5.
34. Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 2000;24:1650-6.
35. Frolik D, Caduff R, Varga Z. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes, and tumor suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas. Histopathology 2001;39:503-13.
36. Kirkegaard T, Witton CJ, McGlynn LM, et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005;207:139-46.
37. Yamashita H, Nishio M, Kobayashi S, et al. Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res 2005;7:753-64.
38. Tokunaga E, Kimura Y, Oki E, et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 2006;118:284-9.
39. Whyte DB, Holbeck SL. Correlation of PIK3CA mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 2006;340:469-75.
40. Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002;16:984-93.